Results 141 to 150 of about 10,523 (190)

Limitations of cholesterol lowering with PCSK9 inhibitors

The Lancet Diabetes & Endocrinology, 2017
openaire   +3 more sources

Evolocumab induced short-term biliary stent blockage and acute cholangitis in a jaundice patient with pancreatic carcinoma: a rare complication of PCSK9 inhibitor. [PDF]

Hepatobiliary Surg Nutr
He K, Wang Y, Chen S, Wang J, Cheng S, Li J, Wang Z.   +6 more
europepmc   +1 more source

Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation. [PDF]

Eur Heart J Cardiovasc Pharmacother
Goodman SG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Harrington RA, Jukema JW, White HD, Zeiher AM, Manvelian G, Pordy R, Poulouin Y, Stipek W, Garon G, Schwartz GG, ODYSSEY OUTCOMES Investigators.   +16 more
europepmc   +1 more source

PCSK9 Inhibitors or Cardiovascular Disease Inhibitors?

Journal of Cardiology & Cardiovascular Therapy, 2016
openaire   +1 more source

Efficacy and safety of inclisiran versus PCSK9 inhibitor versus statin plus ezetimibe therapy in hyperlipidemia: a systematic review and network meta-analysis. [PDF]

BMC Cardiovasc Disord
Zhang S, Sun L, Xu X, Zhang Y, Chen Q.
europepmc   +1 more source

Persistence and Adherence to PCSK9 Inhibitor Monoclonal Antibodies Versus Ezetimibe in Real-World Settings. [PDF]

Adv Ther
Muntner P, Ghazi L, Jones J, Dhalwani N, Poudel B, Wen Y, Chen L, Wang Z, Bittner V, Kalich B, Farkouh ME, Woodward M, Colantonio LD, Rosenson RS.   +13 more
europepmc   +1 more source

PCSK9 inhibitor in acute ischemic stroke patient receiving mechanical thrombectomy: early outcomes and safety. [PDF]

Front Neurol
Kim J, Hong U, Yoon CW, Bae JW, Rha JH, Park HK.   +5 more
europepmc   +1 more source

Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of coronary heart disease: a study protocol for a randomized controlled trial in Dalian, China. [PDF]

Trials
Gong X, Yu X, Pu L, Jiao Y, Liu L, Cao H, Ji X.   +6 more
europepmc   +1 more source